Curated News
By: NewsRamp Editorial Staff
October 09, 2024
Clene (NASDAQ: CLNN) to Present at 2024 Maxim Healthcare Virtual Summit and ThinkEquity Conference 2024
Discuss on Reddit
LinkedIn
Telegram
GithubTLDR
- Clene (NASDAQ: CLNN) will participate in two investor conferences to showcase its potential in treating neurodegenerative diseases, including ALS and MS.
- Clene is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.
- Clene's research and development focus on improving mitochondrial health and protecting neuronal function aim to make tomorrow better for patients with neurodegenerative diseases.
- Clene will present at the 2024 Maxim Healthcare Virtual Summit and ThinkEquity Conference 2024, showcasing its groundbreaking approach to treating neurodegenerative diseases.
Impact - Why it Matters
This news matters as it highlights Clene's efforts to address neurodegenerative diseases, providing potential insights into the future of treatment for conditions like ALS and MS. Investors and those affected by these diseases should take note of Clene's developments in this space.
Summary
Clene (NASDAQ: CLNN) and its subsidiary Clene Nanomedicine Inc. are set to participate in two investor conferences this month, presenting their focus on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.
The company will deliver a virtual presentation at the 2024 Maxim Healthcare Virtual Summit on October 15 and later present at the ThinkEquity Conference 2024 on October 30. Clene's investigational therapy, CNM-Au8(R), targets mitochondrial function and the NAD pathway while reducing oxidative stress.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene (NASDAQ: CLNN) to Present at 2024 Maxim Healthcare Virtual Summit and ThinkEquity Conference 2024
